InterCure Ltd. (INCR)
USD 1.6
(3.23%)
USD 1.6
(3.23%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 329.55 Million ILS | -24.51% |
| 2022 | 436.53 Million ILS | 92.19% |
| 2021 | 227.13 Million ILS | 564.88% |
| 2020 | 34.16 Million ILS | 31.23% |
| 2019 | 26.03 Million ILS | 60.12% |
| 2018 | 16.25 Million ILS | 397.63% |
| 2017 | 3.26 Million ILS | -10.88% |
| 2016 | 3.66 Million ILS | 449.16% |
| 2015 | 667.52 Thousand ILS | -65.65% |
| 2014 | 1.94 Million ILS | -13.5% |
| 2013 | 2.24 Million ILS | -52.13% |
| 2012 | 4.69 Million ILS | -91.41% |
| 2011 | 54.63 Million ILS | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 278.77 Million ILS | 0.0% |
| 2024 Q1 | 278.77 Million ILS | -15.41% |
| 2023 Q3 | 329.55 Million ILS | 4.89% |
| 2023 Q2 | 314.19 Million ILS | -10.92% |
| 2023 FY | 329.55 Million ILS | -24.51% |
| 2023 Q1 | 352.7 Million USD | -19.2% |
| 2023 Q4 | 329.55 Million ILS | 0.0% |
| 2022 Q3 | 361.35 Million ILS | 24.19% |
| 2022 Q4 | 436.53 Million ILS | 20.8% |
| 2022 Q1 | 259.22 Million ILS | 14.13% |
| 2022 Q2 | 290.97 Million ILS | 12.25% |
| 2022 FY | 436.53 Million ILS | 92.19% |
| 2021 Q3 | 205.48 Million ILS | 42.73% |
| 2021 Q4 | 227.13 Million ILS | 10.53% |
| 2021 Q1 | 43.95 Million ILS | 28.66% |
| 2021 FY | 227.13 Million ILS | 564.88% |
| 2021 Q2 | 143.96 Million ILS | 227.55% |
| 2020 FY | 34.16 Million ILS | 31.23% |
| 2020 Q2 | 42.47 Million ILS | 52.5% |
| 2020 Q3 | 39.35 Million ILS | -7.35% |
| 2020 Q4 | 34.16 Million ILS | -13.19% |
| 2020 Q1 | 27.85 Million ILS | 6.98% |
| 2019 FY | 26.03 Million ILS | 60.12% |
| 2019 Q3 | 6.5 Million ILS | -62.92% |
| 2019 Q4 | 26.03 Million ILS | 300.0% |
| 2019 Q1 | 6.5 Million ILS | -59.97% |
| 2019 Q2 | 17.55 Million ILS | 169.67% |
| 2018 Q2 | 4.34 Million ILS | 0.23% |
| 2018 Q3 | 16.25 Million ILS | 274.1% |
| 2018 Q4 | 16.25 Million ILS | 0.0% |
| 2018 FY | 16.25 Million ILS | 397.63% |
| 2018 Q1 | 4.33 Million ILS | 32.72% |
| 2017 Q1 | 4.86 Million ILS | 32.59% |
| 2017 Q3 | 3.43 Million ILS | -26.7% |
| 2017 Q4 | 3.26 Million ILS | -4.78% |
| 2017 FY | 3.26 Million ILS | -10.88% |
| 2017 Q2 | 4.68 Million ILS | -3.7% |
| 2016 Q3 | 3.32 Million ILS | 5.85% |
| 2016 FY | 3.66 Million ILS | 449.16% |
| 2016 Q4 | 3.66 Million ILS | 10.2% |
| 2016 Q2 | 3.14 Million ILS | 2.24% |
| 2016 Q1 | 3.07 Million ILS | 360.45% |
| 2015 Q4 | 667.52 Thousand ILS | -24.83% |
| 2015 Q3 | 887.98 Thousand ILS | -39.91% |
| 2015 Q1 | 2.35 Million ILS | 20.96% |
| 2015 FY | 667.52 Thousand ILS | -65.65% |
| 2015 Q2 | 1.47 Million ILS | -37.12% |
| 2014 Q4 | 1.94 Million ILS | -1.27% |
| 2014 Q3 | 1.96 Million ILS | -17.27% |
| 2014 Q2 | 2.37 Million ILS | 44.23% |
| 2014 Q1 | 1.64 Million ILS | -26.57% |
| 2014 FY | 1.94 Million ILS | -13.5% |
| 2013 Q4 | 2.24 Million ILS | -15.16% |
| 2013 FY | 2.24 Million ILS | -52.13% |
| 2013 Q1 | 4.76 Million ILS | 1.61% |
| 2013 Q2 | 2.87 Million ILS | -39.63% |
| 2013 Q3 | 2.64 Million ILS | -8.02% |
| 2012 FY | 4.69 Million ILS | -91.41% |
| 2012 Q2 | 1.17 Million ILS | 0.0% |
| 2012 Q3 | 3.44 Million ILS | 193.71% |
| 2012 Q4 | 4.69 Million ILS | 36.19% |
| 2012 Q1 | 1.17 Million ILS | -91.41% |
| 2011 Q1 | 13.65 Million ILS | 0.0% |
| 2011 FY | 54.63 Million ILS | 0.0% |
| 2011 Q2 | 13.65 Million ILS | 0.0% |
| 2011 Q3 | 13.65 Million ILS | 0.0% |
| 2011 Q4 | 13.65 Million ILS | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 471.67 Million USD | 30.131% |
| Aquestive Therapeutics, Inc. | 163.9 Million USD | -101.063% |
| Collegium Pharmaceutical, Inc. | 947.87 Million USD | 65.233% |
| Cosmos Health Inc. | 30.25 Million USD | -989.337% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -3781.406% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 50.128% |
| Cronos Group Inc. | 43.73 Million USD | -653.501% |
| Incannex Healthcare Limited | 5.83 Million USD | -5552.693% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -580.26% |
| Lifecore Biomedical, Inc. | 219.8 Million USD | -49.933% |
| Regencell Bioscience Holdings Limited | 219.51 Thousand USD | -150029.378% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -5267.646% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -5267.646% |
| SCYNEXIS, Inc. | 55.45 Million USD | -494.323% |
| Safety Shot Inc | 3.89 Million USD | -8367.325% |
| Theratechnologies Inc. | 98.63 Million USD | -234.099% |
| Alpha Teknova, Inc. | 38.55 Million USD | -754.847% |
| Universe Pharmaceuticals INC | 13.75 Million USD | -2295.987% |
| Pacira BioSciences, Inc. | 704.25 Million USD | 53.206% |
| Sonoma Pharmaceuticals, Inc. | 8.75 Million USD | -3663.728% |
| Dynavax Technologies Corporation | 375.02 Million USD | 12.125% |
| Ironwood Pharmaceuticals, Inc. | 817.36 Million USD | 59.681% |
| Radius Health, Inc. | 804.29 Million USD | 59.026% |
| China SXT Pharmaceuticals, Inc. | 9.19 Million USD | -3483.407% |
| Alvotech | 1.88 Billion USD | 82.495% |
| Intra-Cellular Therapies, Inc. | 136.87 Million USD | -140.776% |
| SIGA Technologies, Inc. | 57.97 Million USD | -468.416% |
| Shineco, Inc. | 47.6 Million USD | -592.312% |
| Silver Spike Investment Corp. | 3 Million USD | -10849.186% |
| Journey Medical Corporation | 56.49 Million USD | -483.288% |
| Petros Pharmaceuticals, Inc. | 21.31 Million USD | -1446.048% |
| Embecta Corp. | 2.03 Billion USD | 83.815% |
| Harrow Health, Inc. | 241.75 Million USD | -36.318% |
| Procaps Group, S.A. | 462.06 Million USD | 28.678% |
| Biofrontera Inc. | 23.13 Million USD | -1324.227% |
| DURECT Corporation | 30.4 Million USD | -983.839% |
| PainReform Ltd. | 2.69 Million USD | -12146.451% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 32.394% |
| OptiNose, Inc. | 194.33 Million USD | -69.579% |
| RedHill Biopharma Ltd. | 20.97 Million USD | -1470.932% |
| Organogenesis Holdings Inc. | 181.36 Million USD | -81.71% |
| Cumberland Pharmaceuticals Inc. | 52.51 Million USD | -527.524% |
| ProPhase Labs, Inc. | 42.54 Million USD | -674.615% |
| Phibro Animal Health Corporation | 725.54 Million USD | 54.579% |
| Procaps Group S.A. | 462.06 Million USD | 28.678% |
| TherapeuticsMD, Inc. | 14.02 Million USD | -2250.25% |
| Viatris Inc. | 27.21 Billion USD | 98.789% |
| Rockwell Medical, Inc. | 30.88 Million USD | -967.133% |
| Aytu BioPharma, Inc. | 90.37 Million USD | -264.633% |
| Tilray Brands, Inc. | 892.11 Million USD | 63.06% |
| PetIQ, Inc. | 645.22 Million USD | 48.925% |
| Talphera, Inc. | 6.29 Million USD | -5139.3% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 67.672% |
| Alimera Sciences, Inc. | 107.35 Million USD | -206.977% |
| Assertio Holdings, Inc. | 148.41 Million USD | -122.046% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | -17281.755% |
| Avadel Pharmaceuticals plc | 173.38 Million USD | -90.067% |
| Hempacco Co., Inc. | 18.82 Million USD | -1650.85% |
| Alvotech | 1.88 Billion USD | 82.495% |
| Lantheus Holdings, Inc. | 835.25 Million USD | 60.545% |
| Kamada Ltd. | 109.96 Million USD | -199.679% |
| Currenc Group, Inc. | 177.67 Million USD | -85.479% |
| Indivior PLC | 1.95 Billion USD | 83.111% |
| Evoke Pharma, Inc. | 9.64 Million USD | -3315.725% |
| Flora Growth Corp. | 17.22 Million USD | -1813.552% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -3781.406% |
| Evolus, Inc. | 209.68 Million USD | -57.164% |
| HUTCHMED (China) Limited | 536.38 Million USD | 38.561% |
| Amphastar Pharmaceuticals, Inc. | 873.49 Million USD | 62.272% |
| Akanda Corp. | 12.66 Million USD | -2501.271% |